Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SRDX 
SurModics Inc (SRDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SRDX (2-star) is a SELL. SELL since 2 days. Profits (10.73%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $43
1 Year Target Price $43
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.9% | Avg. Invested days 45 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 490.84M USD | Price to earnings Ratio - | 1Y Target Price 43 |
Price to earnings Ratio - | 1Y Target Price 43 | ||
Volume (30-day avg) 2 | Beta 1.31 | 52 Weeks Range 26.00 - 40.38 | Updated Date 08/29/2025 |
52 Weeks Range 26.00 - 40.38 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.59% | Operating Margin (TTM) 0.2% |
Management Effectiveness
Return on Assets (TTM) -0.52% | Return on Equity (TTM) -15.36% |
Valuation
Trailing PE - | Forward PE 208.33 | Enterprise Value 490691397 | Price to Sales(TTM) 4.06 |
Enterprise Value 490691397 | Price to Sales(TTM) 4.06 | ||
Enterprise Value to Revenue 4.06 | Enterprise Value to EBITDA 179.57 | Shares Outstanding 14297600 | Shares Floating 12268504 |
Shares Outstanding 14297600 | Shares Floating 12268504 | ||
Percent Insiders 3.4 | Percent Institutions 90.81 |
Upturn AI SWOT
SurModics Inc
Company Overview
History and Background
SurModics, Inc. was founded in 1979. Initially focused on surface modification technologies, it has evolved into a provider of medical device and in vitro diagnostic technologies to the healthcare industry. It went public in 1986 and was acquired by GTCR in 2024.
Core Business Areas
- Medical Device: This segment develops, manufactures, and licenses surface modification technologies and drug delivery technologies for medical devices, including coatings for vascular, orthopedic, and ophthalmic applications.
- In Vitro Diagnostics (IVD): This segment develops and manufactures IVD components and reagent kits used in a variety of diagnostic assays. It offers products and services in areas such as protein stabilization and immunoassay development.
Leadership and Structure
The leadership team consists of key executives overseeing various departments, including R&D, sales, and operations. As a private company, its current leadership structure is not publicly disclosed.
Top Products and Market Share
Key Offerings
- Radiopaque Coatings: Coatings that allow medical devices to be visible under X-ray. Market share difficult to determine precisely, competitors include Hydromer, AST Products. Revenue from these products constitutes a significant portion of the medical device revenue.
- Serologicals: In vitro diagnostic reagents, particularly protein stabilizers. Competitors include Roche Diagnostics, Abbott, Thermo Fisher Scientific. Contribution to IVD revenue is substantial.
- Drug Delivery Technologies: Sustained release and localized drug delivery systems. Market share is not publicly specified. Competitors include DSM Biomedical. Revenue varies depending on licensing deals and product launches.
Market Dynamics
Industry Overview
The medical device and IVD industries are characterized by innovation, stringent regulatory requirements, and increasing demand due to aging populations and advancements in medical technology.
Positioning
SurModics occupies a niche position as a technology provider to medical device and diagnostic companies, rather than a direct competitor selling finished devices or diagnostics. Their competitive advantage is in their specialized surface modification and drug delivery technologies.
Total Addressable Market (TAM)
The TAM for surface modification and drug delivery technologies in medical devices and IVD is estimated to be in the billions of dollars annually. SurModics is positioned to capture a share of this TAM through its licensing agreements and product sales.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Strong intellectual property portfolio
- Established relationships with medical device and diagnostic companies
- Expertise in surface modification and drug delivery
- High regulatory compliance standards.
Weaknesses
- Reliance on licensing agreements
- Dependence on key customers
- Limited direct sales force
- Small size compared to major competitors
Opportunities
- Expanding into new therapeutic areas
- Developing next-generation technologies
- Entering new geographic markets
- Acquiring complementary technologies
- Expanding drug delivery systems
Threats
- Competition from larger companies
- Patent expirations
- Regulatory changes
- Technological obsolescence
- Economic downturn impacts on healthcare spending
Competitors and Market Share
Key Competitors
- HYD
- ABT
- ROSY
- TMO
Competitive Landscape
SurModics is a specialized technology provider in a market dominated by larger players. Its strength lies in its proprietary technologies and established relationships, while its disadvantage is its smaller scale and reliance on licensing agreements.
Major Acquisitions
Creagh Medical
- Year: 2020
- Acquisition Price (USD millions): 27
- Strategic Rationale: Expanded SurModics' capabilities in drug-coated balloon (DCB) technology and structural heart.
Growth Trajectory and Initiatives
Historical Growth: Before acquisition, SurModics experienced moderate growth driven by its core technologies and strategic acquisitions.
Future Projections: Future growth projections are not publicly available since the company is now private. Growth will depend on GTCR's investment strategy and management decisions.
Recent Initiatives: Before acquisition, initiatives included developing new surface modification technologies, expanding the IVD product portfolio, and entering strategic partnerships.
Summary
SurModics, prior to being acquired, was a solid technology provider with key intellectual property in surface modification and drug delivery. Their acquisition by GTCR reflects the value of its technologies. Going forward, its success will depend on GTCR's strategic investments and management. Before this acquisition, key risks revolved around competition and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SurModics Inc. Investor Relations
- SEC Filings (prior to acquisition)
- Industry Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information prior to SurModics' acquisition by GTCR. Forward-looking statements are subject to uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SurModics Inc
Exchange NASDAQ | Headquaters Eden Prairie, MN, United States | ||
IPO Launch date 1998-03-04 | CEO, President & Director Mr. Gary R. Maharaj | ||
Sector Healthcare | Industry Medical Devices | Full time employees 389 | Website https://www.surmodics.com |
Full time employees 389 | Website https://www.surmodics.com | ||
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.